Wedbush Reiterates “Outperform” Rating for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “outperform” rating reiterated by research analysts at Wedbush in a report issued on Tuesday,RTT News reports. They currently have a $9.00 price target on the stock, down from their prior price target of $11.00. Wedbush’s price objective suggests a potential upside of 103.62% from the stock’s previous close.

Several other equities analysts have also weighed in on VYGR. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Monday, January 27th. Cantor Fitzgerald began coverage on shares of Voyager Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating and a $5.73 target price for the company. Citigroup initiated coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Finally, Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Voyager Therapeutics has a consensus rating of “Buy” and a consensus price target of $15.72.

Voyager Therapeutics Stock Up 5.2 %

VYGR stock opened at $4.42 on Tuesday. The firm has a market cap of $241.46 million, a PE ratio of 6.23 and a beta of 0.91. The business has a 50 day moving average of $5.65 and a 200-day moving average of $6.32. Voyager Therapeutics has a 12-month low of $4.00 and a 12-month high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. During the same quarter in the previous year, the firm earned ($0.59) earnings per share. On average, research analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Transactions at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the sale, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 10,778 shares of company stock valued at $58,548 over the last three months. Company insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds have recently bought and sold shares of the company. ExodusPoint Capital Management LP boosted its holdings in Voyager Therapeutics by 99.5% in the 4th quarter. ExodusPoint Capital Management LP now owns 65,830 shares of the company’s stock valued at $373,000 after purchasing an additional 32,834 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Voyager Therapeutics by 8.2% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 186,000 shares of the company’s stock valued at $1,055,000 after purchasing an additional 14,144 shares in the last quarter. Geode Capital Management LLC lifted its position in Voyager Therapeutics by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company’s stock valued at $6,149,000 after purchasing an additional 4,729 shares during the last quarter. Wellington Management Group LLP grew its stake in Voyager Therapeutics by 13.9% in the 4th quarter. Wellington Management Group LLP now owns 261,251 shares of the company’s stock worth $1,481,000 after buying an additional 31,882 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Voyager Therapeutics by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 3,215,441 shares of the company’s stock worth $18,232,000 after buying an additional 29,014 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.